Related Experiment Video
Updated: Aug 9, 2026
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Carbohydrate vaccines for the immunotherapy of cancer
1Immunology Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. k-lloyd@ski.mskcc.org
Abstract:
On the basis of the observation that tumor cells exhibit aberrant glycosylation, carbohydrate vaccines are being developed for the active immunotherapy of cancer. Potential targets include members of the ABH Lewis blood group family (e.g., Lewis(y)), members of the mucin core family (e.g., Tn, sialyl Tn and T-F) and gangliosides (e.g., GM2). Most studies have used glycoconjugate vaccines in which a synthetic oligosaccharide is coupled to a protein carrier, for example, KLH, but completely synthetic constructs are also being examined. Preclinical studies in mice have shown the effectiveness of some of these vaccines. Clinical studies are under way in a number of human cancers but the results are still being evaluated.
Insights
Carbohydrate vaccines targeting aberrant tumor cell glycosylation are being developed for cancer immunotherapy. Preclinical studies show effectiveness, and clinical trials are ongoing for various human cancers.
Area of Science:
- Oncology
- Immunology
- Carbohydrate Chemistry
Background:
- Tumor cells display abnormal glycosylation patterns, presenting unique targets for cancer therapy.
- Aberrant glycosylation is a hallmark of cancer, making carbohydrate structures potential biomarkers and therapeutic targets.
Purpose of the Study:
- To explore the development and efficacy of carbohydrate vaccines for active cancer immunotherapy.
- To investigate specific carbohydrate antigens, including Lewis(y), Tn, sialyl Tn, T-F antigens, and GM2 gangliosides, as targets for cancer vaccines.
Main Methods:
- Development of glycoconjugate vaccines by coupling synthetic oligosaccharides to protein carriers (e.g., KLH).
- Evaluation of completely synthetic vaccine constructs.
- Preclinical testing of vaccine efficacy in mouse models.
Main Results:
- Preclinical studies in mice demonstrated the effectiveness of certain carbohydrate-based vaccines.
- Clinical trials are currently underway in patients with various human cancers.
Conclusions:
- Carbohydrate vaccines represent a promising strategy for active cancer immunotherapy.
- Further evaluation of ongoing clinical trials is necessary to determine the full therapeutic potential of these vaccines.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...